Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
about
Development of Novel Immunotherapies for Multiple MyelomaT-cell receptor gene therapy--ready to go viral?How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferDirect tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.Th17 cells are long lived and retain a stem cell-like molecular signatureSpecific increase in potency via structure-based design of a TCR.Engineering improved T cell receptors using an alanine-scan guided T cell display selection systemMolecular characterization of T cell receptor beta variable in the peripheral blood T cell repertoire in subjects with active tuberculosis or latent tuberculosis infection.Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B.Challenges and future perspectives of T cell immunotherapy in cancerPhenotypes and clinical significance of circulating CD4(+)CD25(+) regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF).T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapyCollapse of the tumor stroma is triggered by IL-12 induction of Fas.Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets.Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle deliveryEGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.Notch and inflammatory T-cell response: new developments and challenges.Challenges in T cell receptor gene therapy.Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.Optimizing T-cell receptor gene therapy for hematologic malignancies.Cancer testis antigen and immunotherapy.Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function.N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.A Nontoxic Transduction Enhancer Enables Highly Efficient Lentiviral Transduction of Primary Murine T Cells and Hematopoietic Stem Cells
P2860
Q28066890-868B2DD2-C237-43A6-BBBD-A4FB77F647AAQ28081611-0ADE9403-13AA-46DF-99B9-B5A23EC1E07FQ28727481-05FBA396-8954-44FA-A820-F05DBC95B40FQ30667174-8F707FB2-D79F-45E2-AF47-A552A6CF8711Q34079604-E002390C-2F7D-4B1D-82E2-32685157624EQ34241261-88D7A97B-2A92-4FAA-8D6F-119E307B523EQ34383054-A55A60A2-F05B-42FD-A23C-6CB25EF6B04FQ34624124-4DFB9AFD-CA80-4221-AAB2-23A939508673Q34980349-04EF08A1-01E7-4806-B9D6-E8A45ED9C813Q35145392-D980C548-3BE7-4925-8C7F-CE66674677AAQ35162266-120F3DF4-AC72-435C-84FE-35787FDB2149Q35578622-78D728F0-B9C9-409B-A0D8-494A80005752Q35666734-E8D4C456-B357-435F-8D29-E1DB95DD11CAQ35843507-57A417E8-005E-42BB-95A8-1CD61756E948Q36480611-C683F65F-6D41-4826-B892-287D56472914Q36799229-077B0049-7AE5-494C-AB1D-CD4D8D8909F8Q36984473-8F772E53-0A77-420D-98A2-8098CC85C48DQ37072024-22E808E5-A4D1-416B-AD86-914CE8B00A5DQ37164976-4B69FECE-8009-4FF8-A3B2-EAAAEE2061A3Q37618652-8B0AC10A-1ECD-47DB-8632-BDDC130A21E1Q37952793-705D7271-C2DF-4E47-AA92-E6B12318C10AQ38011650-0F9A255E-D880-4981-8A5C-86459513CB9FQ38802594-07CFC64A-1DBD-4EB7-8083-852C56CF432BQ38840466-61E53B87-CB35-4D38-8931-0F6A625AF410Q38912232-23A14E44-DC34-4AB7-9C6B-85531AAA4879Q39280062-22246B0E-8FB3-4BD6-BB29-EF698DE65309Q40063172-AE6BF83E-27FC-4F58-961C-895E14598348Q48112031-D05C06F4-1A7E-4C0F-8123-0B0F01C4F56DQ50054341-AE49A564-FC33-47E1-8F88-05E2040FED13Q58794963-48B3CDD0-53B9-4CC8-A715-D015E4864C65
P2860
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic engineering of murine ...... doptive immunotherapy studies.
@ast
Genetic engineering of murine ...... doptive immunotherapy studies.
@en
type
label
Genetic engineering of murine ...... doptive immunotherapy studies.
@ast
Genetic engineering of murine ...... doptive immunotherapy studies.
@en
prefLabel
Genetic engineering of murine ...... doptive immunotherapy studies.
@ast
Genetic engineering of murine ...... doptive immunotherapy studies.
@en
P2093
P2860
P1476
Genetic engineering of murine ...... adoptive immunotherapy studies
@en
P2093
Andrew D M Kaiser
Christian S Hinrichs
Christopher D Scott
Dhanalakshmi Chinnasamy
Luca Gattinoni
Luis Sanchez-Perez
Pawel Muranski
Richard A Morgan
Shicheng Yang
Sid P Kerkar
P2860
P304
P356
10.1097/CJI.0B013E3182187600
P577
2011-05-01T00:00:00Z